Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,835Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-84.5EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)22.5Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %2.2PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M12,650,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IYH

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

IYH is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!

IYH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BEST, SIMON GEOFFREYDirector 2016-10-07Buy2,750$2.934849.49view
Camilli, Kathleen MaryDirector 2016-10-07Buy5,000$4.992806.21view
Breault, Robert PaulDirector 2016-10-07Sell68,500$0.7120325.35view
Meade, Harlan DonnleyDirector, Senior Officer 2016-10-07Buy3,000$0.1690537.5view
Lemasson, ClaudeDirector, Senior Officer 2016-10-07Buy100,000$0.818027.5view
ESTEPA, JORGEDirector or Senior Officer of 10% Security Holder, 2016-10-07Buy3,500$0.436155view
Griffiths, Richard Ian10% Security Holder 2016-10-07Buy89,500$036155view
Hinchcliffe, Robert10% Security Holder, Director, Senior Officer 2016-10-07Buy3,500$0.4432859.09view
Reeson, DouglasDirector, Senior Officer 2016-10-07Buy15,000$0.08181175view
Anderson, Christopher RossDirector 2016-10-07Buy28,000$0.14103485.71view

Quarterly/Annual Reports about IYH:

    News about IYH:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    J&J Beats on Q3 Earnings: Should You Buy Healthcare ETFs? Oct 18 2016
    3 ETFs to Buy if You Think Johnson & Johnson Will Beat Earnings Oct 17 2016
    Four Key Deals: Analyzing Pfizer’s Impending Growth Oct 14 2016
    Does Pfizer Deserve a Better Valuation? Oct 13 2016
    How Large of a Role Does Opdivo Play in Bristol-Myers Squibb’s Success? Oct 12 2016
    Bristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market Oct 11 2016
    Understanding the Recent Fall in Bristol-Myers Squibb’s Valuation Oct 07 2016
    Shareholder Buyback: A Powerful Tool to Achieve Higher Income Oct 04 2016
    Will Sales of Xeljanz Offset Falling Sales of Enbrel? Sep 05 2016
    How Pfizer Plans to Extend Ibrance beyond Breast Cancer Treatment Sep 02 2016
    A Look at the Drugs That Are Driving Eli Lilly’s Revenues Sep 01 2016
    Why Pfizer’s Valuation Is Suffering Aug 31 2016
    Ibrance and Xtandi Could Be in the Top 10 Oncology Drugs by 2021 Aug 29 2016
    AbbVie Launched Zinbryta in the US in August Aug 25 2016
    Is Eli Lilly Rebounding from Patent Expiry of Cymbalta? Aug 01 2016
    3 Healthcare ETFs to Buy as JNJ Beats Q2 Earnings Jul 21 2016
    Despite Swings, Stock ETF Outlook Still Looks Strong Jul 07 2016
    How Healthcare ETFs Could Really Get it Together Jun 24 2016
    These Sector ETFs Could Lead the Market Higher Jun 09 2016
    Carl Icahn Just Bought Shares of Allergan -- Should You? Jun 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)